Intriguing! Could you supply a link to the article you read, goodcheers?

Google AI found this comment:

NCA033989 (formerly referred to in early development as INCA44989) is a first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody currently in clinical trials for essential thrombocythemia (ET). It targets the underlying drivers of the disease rather than just managing symptoms.

. . . please note, this antibody is being tested for those with the CALR driver (rather than the JAK driver).

If you go to the top of this page and in the search box type "drbart86" -- you will meet someone actively participating in this trial.

It is VERY exciting indeed!